Venus Vakhshori1, Sofia Bougioukli2, Osamu Sugiyama2, Hyunwoo P Kang2, Amy H Tang2, Sang-Hyun Park3, Jay R Lieberman4. 1. Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, 1520 San Pablo Street, Suite 2000, Los Angeles, CA 90033, United States of America. Electronic address: venus.vakhshori@med.usc.edu. 2. Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, 1520 San Pablo Street, Suite 2000, Los Angeles, CA 90033, United States of America. 3. Orthopaedic Institute for Children, J. Vernon Luck Sr. Orthopaedic Research Center, University of California, Los Angeles, 403 West Adams Boulevard, Los Angeles, CA 90007, United States of America. 4. Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, 1520 San Pablo Street, Suite 2000, Los Angeles, CA 90033, United States of America. Electronic address: jay.lieberman@med.usc.edu.
Abstract
BACKGROUND: The treatment of complex bone loss scenarios remains challenging. This study evaluates the efficacy of ex vivo regional gene therapy using transduced human adipose-derived stem cells (ASCs) overexpressing bone morphogenetic protein-2 (BMP-2) to treat critical-sized bone defects. METHODS: Critical-sized femoral defects created surgically in immunocompromised rats were treated with ASCs transduced with a lentivirus encoding BMP-2 (Group 1, n = 14), or green fluorescent protein (Group 2, n = 5), nontransduced ASCs (Group 3, n = 5), or rhBMP-2 (Group 4, n = 14). At 12 weeks, femurs were evaluated for quantity and quality of bone formation with plain radiographs, micro-computed tomography, histology/histomorphometry, and biomechanical strength testing. RESULTS: Thirteen of 14 samples in Group 1 and all 14 samples in Group 4 showed radiographic healing, while no samples in either Groups 2 or 3 healed. Groups 1 and 4 had significantly higher radiographic scores (p < 0.001), bone volume fraction (BV/TV) (p < 0.001), and bone area fraction (BA/TA) than Groups 2 and 3 (p < 0.001). Radiographic scores, BV/TV, and BA/TA were not significantly different between Groups 1 and 4. No difference with regards to mean torque, rotation at failure, torsional stiffness, and energy to failure was seen between Groups 1 and 4. CONCLUSIONS: Human ASCs modified to overexpress BMP-2 resulted in abundant bone formation, with the quality of bone comparable to that of rhBMP-2. This strategy represents a promising approach in the treatment of large bone defects in the clinical setting. CLINICAL RELEVANCE: Large bone defects may require sustained protein production to induce an appropriate osteoinductive response. Ex vivo regional gene therapy using a lentiviral vector has the potential to be part of a comprehensive tissue engineering strategy for treating osseous defects.
BACKGROUND: The treatment of complex bone loss scenarios remains challenging. This study evaluates the efficacy of ex vivo regional gene therapy using transduced human adipose-derived stem cells (ASCs) overexpressing bone morphogenetic protein-2 (BMP-2) to treat critical-sized bone defects. METHODS: Critical-sized femoral defects created surgically in immunocompromised rats were treated with ASCs transduced with a lentivirus encoding BMP-2 (Group 1, n = 14), or green fluorescent protein (Group 2, n = 5), nontransduced ASCs (Group 3, n = 5), or rhBMP-2 (Group 4, n = 14). At 12 weeks, femurs were evaluated for quantity and quality of bone formation with plain radiographs, micro-computed tomography, histology/histomorphometry, and biomechanical strength testing. RESULTS: Thirteen of 14 samples in Group 1 and all 14 samples in Group 4 showed radiographic healing, while no samples in either Groups 2 or 3 healed. Groups 1 and 4 had significantly higher radiographic scores (p < 0.001), bone volume fraction (BV/TV) (p < 0.001), and bone area fraction (BA/TA) than Groups 2 and 3 (p < 0.001). Radiographic scores, BV/TV, and BA/TA were not significantly different between Groups 1 and 4. No difference with regards to mean torque, rotation at failure, torsional stiffness, and energy to failure was seen between Groups 1 and 4. CONCLUSIONS:HumanASCs modified to overexpress BMP-2 resulted in abundant bone formation, with the quality of bone comparable to that of rhBMP-2. This strategy represents a promising approach in the treatment of large bone defects in the clinical setting. CLINICAL RELEVANCE: Large bone defects may require sustained protein production to induce an appropriate osteoinductive response. Ex vivo regional gene therapy using a lentiviral vector has the potential to be part of a comprehensive tissue engineering strategy for treating osseous defects.
Authors: J R Lieberman; A Daluiski; S Stevenson; L Wu; P McAllister; Y P Lee; J M Kabo; G A Finerman; A J Berk; O N Witte Journal: J Bone Joint Surg Am Date: 1999-07 Impact factor: 5.284
Authors: P Garcia; T Histing; J H Holstein; M Klein; M W Laschke; R Matthys; A Ignatius; B Wildemann; J Lienau; A Peters; B Willie; G Duda; L Claes; T Pohlemann; M D Menger Journal: Eur Cell Mater Date: 2013-07-16 Impact factor: 3.942
Authors: Mandeep S Virk; Farhang Alaee; Hezhen Tang; Michael S Ominsky; Hua Zhu Ke; Jay R Lieberman Journal: J Bone Joint Surg Am Date: 2013-04-17 Impact factor: 5.284
Authors: Volker M Betz; Oliver B Betz; Tom Rosin; Alexander Keller; Christian Thirion; Michael Salomon; Suzanne Manthey; Peter Augat; Volkmar Jansson; Peter E Müller; Stefan Rammelt; Hans Zwipp Journal: Injury Date: 2015-09-28 Impact factor: 2.586
Authors: Kevin Collon; Jennifer A Bell; Matthew C Gallo; Stephanie W Chang; Sofia Bougioukli; Osamu Sugiyama; Jade Tassey; Roger Hollis; Nathanael Heckmann; Daniel A Oakes; Donald B Longjohn; Denis Evseenko; Donald B Kohn; Jay R Lieberman Journal: Gene Ther Date: 2022-10-11 Impact factor: 4.184
Authors: Bin Ren; Oliver B Betz; Daniel Seitz; Christian Thirion; Michael Salomon; Volkmar Jansson; Peter E Müller; Volker M Betz Journal: Int J Mol Sci Date: 2022-02-28 Impact factor: 5.923
Authors: Rachael S Watson-Levings; Glyn D Palmer; Padraic P Levings; E Anthony Dacanay; Christopher H Evans; Steven C Ghivizzani Journal: Front Bioeng Biotechnol Date: 2022-06-28
Authors: Peer W Kämmerer; Vivien Engel; Franz Plocksties; Anika Jonitz-Heincke; Dirk Timmermann; Nadja Engel; Bernhard Frerich; Rainer Bader; Daniel G E Thiem; Anna Skorska; Robert David; Bilal Al-Nawas; Michael Dau Journal: Biomedicines Date: 2020-11-08